NCT02691117 is a Phase 3 clinical trial of garlic concentrate in Alopecia Areata, sponsored by Elena Pope.

Who is sponsoring NCT02691117?

NCT02691117 is sponsored by Elena Pope.

What drugs are being tested in NCT02691117?

Interventions in NCT02691117: garlic concentrate.

What condition does NCT02691117 study?

NCT02691117 studies Alopecia Areata.

Is NCT02691117 still recruiting?

NCT02691117 is currently terminated. Last updated 19 April 2018.

Last reviewed 2018-04-19 · How we verify

NCT02691117

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Garlic Concentrate for Alopecia Areata in Children

Terminated Phase 3 Last updated 19 April 2018

What this trial tests

Phase 3 trial testing garlic concentrate in Alopecia Areata in 8 participants. Terminated before completion.

Timeline

10 January 2016

Primary endpoint
15 August 2017

1 December 2017

Quick facts

Lead sponsor	Elena Pope
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	10 January 2016
Primary completion	15 August 2017
Estimated completion	1 December 2017
Sites	1 location across Canada

Drugs / interventions tested

garlic concentrate — full drug profile →

Conditions studied

Alopecia Areata — all drugs for Alopecia Areata →

Sponsor

Elena Pope — full company profile →

Who can join

Adults 4 to 18, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Management of pediatric alopecia is particularly challenging given the chronicity of the condition, limited therapeutic response and devastating psychological effects. There is a paucity of safe and effective therapies in this population. The investigators propose to conduct and open label, prospective cohort pilot study using topical garlic concentrate ( GarlicRich) for treatment of children with alopecia areata. Study medication will be applied topically on affected area of the skin daily for 6 months. Follow up visits will occur monthly to access the efficacy and safety of the proposed treatment .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alopecia Areata

Currently open trials in the same condition.

NCT07242638 — Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome · Phase 2 · recruiting
NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
NCT07205159 — A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. · Phase 1 · recruiting
NCT06747611 — Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata · Phase 2 · recruiting

Other Elena Pope trials

Trials by the same sponsor.

NCT04613102 — The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial · Phase 2, PHASE3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02691117 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elena Pope
Last refreshed: 19 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02691117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing